DIA’s 2026 Real-World Evidence Conference: Moving RWE from acceptance to scale | Becaris Publishing

Building confidence in transportability analyses through a structured framework: Insights from Blythe Adamson and Grammati Sarri | Becaris Publishing

Sink or swim? Debating the need for more RWE guidance with Ashley Jaksa and Sandipan Bhattacharjee | Becaris Publishing

Nested Knowledge and EviValue collaborate on AI-enabled evidence synthesis and HEOR | Becaris Publishing

Another JCA initiated as daraxonrasib enters EU HTA process alongside EMA phased review | Becaris Publishing

FDA selects Dexcom as first participant for TEMPO pilot to advance real-world evidence in digital health | Becaris Publishing

Evidence generation shouldn't end with publication: Why every HEOR and RWE publication needs a plain language strategy | Becaris Publishing

Ireland’s NCPE applies EU Joint Clinical Assessment in first national HTA review | Becaris Publishing

Examining the implementation of RWD quality frameworks in oncology | Becaris Publishing

Key takeaways from the GetReal Conference 2026: From JCA to post-approval evidence | Becaris Publishing

NIH expands All of Us into the world’s largest integrated genomic and EHR research database | Becaris Publishing

Samsung and Alcedis to advance wearable-based endpoints in clinical research | Becaris Publishing

Two discontinued JCAs reveal emerging evidence standards as EU HTA assessments gather pace | Becaris Publishing

Insights into ALZ-NET and real-world evidence generation in Alzheimer’s disease: A conversation with Rebecca Edelmayer, Alzheimer's Association | Becaris Publishing

Improving transparency in target trial emulation: The TARGET guideline with Aidan Cashin, University of New South Wales | Becaris Publishing

Becaris Publishing

EFPIA report highlights widening disparities in access to innovative medicines across Europe | Becaris Publishing

UK’s MHRA and NICE formalize early RWE dialogue initiative following pilot | Becaris Publishing

Trump Administration outlines projected savings from MFN drug pricing framework | Becaris Publishing

New HEMA project to assess approaches for handling uncertainty in economic evaluation | Becaris Publishing

TEHDAS2 launches final consultation round on EHDS secondary use guidance | Becaris Publishing

Strengthening research through meaningful public and patient involvement | Becaris Publishing

What to attend at ISPOR 2026: Exploring the conference program with Laura Pizzi | Becaris Publishing

UK Biobank data breach raises renewed questions in safeguarding secondary health data | Becaris Publishing

Is expanded access to GLP-1 medicines hanging in the BALANCE as CMS delays its payment and coverage model? | Becaris Publishing

Perspectives from the Healthcare Economist: Two visions for value – Why GCEA and HEMA clash on drug pricing | Becaris Publishing

A new framework for patient engagement in rare disease HTA: Rick Chapman and Michelle Cheng of IVI on the Rare Disease Patient Engagement Guidance and Checklist | Becaris Publishing

FDA shares insights on growing use of real-world evidence in medical device approvals | Becaris Publishing

Value Viewpoint: Prying open the pharmacy benefit manager black box to decode the 2026 PBM reforms | Becaris Publishing

Can I trust agentic AI? Validating autonomous analytics for real-world data | Becaris Publishing

EMA publishes final real world data chapter of EU Data Quality Framework | Becaris Publishing

New ABPI report sets out plan to accelerate UK clinical trials using NHS data | Becaris Publishing

New real-world data platform launched to support Alzheimer’s research | Becaris Publishing

Becaris Publishing

Your guide to the World Evidence, Pricing and Access Congress 2026: Key sessions on pricing, EU HTA, innovation and sustainability | Becaris Publishing

Market access and HTA developments with Sreeram Ramagopalan: US–UK policy updates and evolving US drug pricing reforms | Becaris Publishing

ISPOR’s Laura Pizzi and Mitch Higashi on the 2026–2027 Top 10 HEOR Trends and their implications for evidence and access | Becaris Publishing

Gamechanger for UK research as NHS England advances consented GP data access | Becaris Publishing

Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospec...

Why misaligned evidence strategies delay patient access to medicines | Becaris Publishing

BC Platforms and OmicsBank launch collaboration to grow real-world and multi-omics evidence from India and the UAE | Becaris Publishing

TrumpRx launches to lower US drug prices, but early reaction is mixed | Becaris Publishing

Rare disease outcome assessment under EU HTA and joint clinical assessment | Becaris Publishing

Hot off the press: Part one of our pick of articles within HTA and RWE published in January 2026 | Becaris Publishing

Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial

Head-to-head real-world study reports overall survival advantage with apalutamide compared with darolutamide in metastatic castration-sensitive prostate cancer | Becaris Publishing

Industry update tracker: January 2026 | Becaris Publishing

Patient roles and expectations in effective HTA engagement | Becaris Publishing

Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer